

**NAGOYA PROTOCOL**  
**ON**  
**ACCESS TO GENETIC RESOURCES**  
**AND THE FAIR AND EQUITABLE**  
**SHARING OF BENEFITS ARISING**  
**FROM THEIR UTILIZATION**  
**TO THE**  
**CONVENTION ON**  
**BIOLOGICAL DIVERSITY**

**TEXT AND ANNEX**



**CBD**



**COP10/MOP5**  
**AICHI-NAGOYA**  
**JAPAN 2010**

**In force since 12 October 2014**

## *The Nagoya Protocol: key elements*

- Implements **art. 15 of CBD** – third pillar of the Convention (ABS)
- Establishes an **International framework of common rules** on access to genetic resources and/or traditional Knowledge associated to GRs
- Aims at ensuring the **fair and equitable sharing of benefits** arising from utilization of GRs (monetary and/or non monetary)
- Contributes to the **conservation of Biological diversity** and the **sustainable use of its components**



## *The Pillars of the Protocol*

- ✓ Access Pillar : access to GRs according to specific measures (PIC and MAT)
- ✓ Compliance Pillar : utilization of GRs has to be legal = monitoring mechanism through checkpoints




Aim:

- ✓ Legal certainty
- ✓ Legal clarity
- ✓ Legal transparency

# Key themes

- IN-SITU**
  - FOUND WITHIN ECOSYSTEMS AND NATURAL HABITATS
- EX-SITU**
  - FOUND IN BOTANICAL GARDENS, COMMERCIAL OR UNIVERSITY COLLECTIONS
- NON-COMMERCIAL**
  - TAXONOMY
  - CONSERVATION
- COMMERCIAL**
  - BIOTECHNOLOGY
  - HORTICULTURE
  - PHARMACEUTICALS



- STATES HAVE SOVEREIGN RIGHTS OVER NATURAL RESOURCES
- COMPETENT NATIONAL AUTHORITIES (CNAs) IN THESE STATES GRANT USERS ACCESS TO THESE RESOURCES

- RESEARCHERS
- UNIVERSITIES
- INDUSTRIES

- MONETARY**
  - ROYALTY PAYMENTS
  - JOINT OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS
- NON-MONETARY**
  - RESEARCH AND DEVELOPMENT
  - TRAINING AND EDUCATION
  - TRANSFER OF TECHNOLOGY

There are five key themes that underpin access and benefit-sharing of genetic resources. These are covered in a series of factsheets, which tackle each theme individually.

# Utilization

*Utilization = “to conduct research and development on the genetic and/or biochemical composition of genetic resources, including through the application of biotechnology” (art. 2 (c) of NP – art. 3 (5) of EU Regulation)*

- ✓ No close list of activities = not to pre-empt changes in the evolving technology.
- ✓ Utilization = both basic and applied research.
- ✓ Access regulations in provider countries are not unanimous = different conditions for different types of utilization



# The Nagoya Protocol state of play up to December 2018



About the ABSCH

Search

Submit

Country Profiles ▾

National Reports

The Access and Benefit-Sharing Clearing-House (ABSCH) is a platform for exchanging information on ABSCH and a key tool for facilitating the implementation of the Nagoya Protocol. ⓘ



## National Records

- 172 ABS National Focal Point
- 102 Competent National Authority
- 224 Legislative, Administrative or Policy Measure
- 0 ABS Procedure
- 0 National Model Contractual Clause
- 301 Internationally Recognized Certificates of Compliance
- 44 National Websites or Databases
- 52 Checkpoint

110 Parties to the Nagoya Protocol

4 Ratified, not yet Party

88 Non-Parties



**REGULATION (EU) NO 511/2014**

*on compliance measures for users from the Nagoya Protocol in the Union*

**9 June 2014:** ABS Regulation in force

**12 October 2014:** ABS Regulation is applicable





## *Scope of the EU Regulation (when the Regulation applies?)*

- ✓ *Geographic Scope* (provider country)
- ✓ *Temporal scope* (time of access and utilization)
- ✓ *Material scope* (type of GRs)
- ✓ *Personal scope* (all users in the EU territory)

**The Regulation is applicable**



# *Scope of the EU Regulation (when the Regulation applies?)*

## *Geographic Scope*


The Provider Country:

*a. **exercises** its sovereign rights over GRs (art. 15 CBD, art. 6 NP)*

- No GRs from high seas*
- No GRs from areas covered by Antarctic Treaty System*
- No Grs from States that do not exercise their sovereign rights*


*a. has **ratified** the Nagoya Protocol*

*a. has **access regulation***



# *Scope of the EU Regulation (when the Regulation applies?)*

## *Temporal Scope*




***Scope of the EU Regulation  
(when the Regulation applies?)  
Material Scope***

*No human genetic resources*



*No plant GRs for Food and Agriculture in Annex I of  
ITPGRFA /FAO*



*No GR covered by the WHO's Pandemic Influenza Preparedness  
Framework (PIP)*

**Pandemic influenza  
preparedness Framework**  
for the sharing of influenza viruses  
and access to vaccines and  
other benefits

*Scope of the EU Regulation  
(when the Regulation applies?)  
Material Scope*

*NO Genetic Resources as traded commodities  
(agricultural, fishery, forestry products)*


**BUT**



# *Scope of the EU Regulation (when the Regulation applies?)*

## *Personal Scope*

*All users utilizing the GR in the EU territory*



**INDIVIDUALS**

**RESEARCHERS**

**UNIVERSITIES**

**RESEARCH ORGANIZATIONS**

**SMEs**

**MULTINATIONAL COMPANIES**



## *Regulation (EU) no 511/2014: basic rules*

- a) Does **NOT** regulate access*
- b) Regulates the **compliance pillar** of the NP*
- c) Introduces the due diligence obligation - “**due diligence**”*
- d) Attention to: a) plant GRs for Food and Agriculture (PGRFA) not in Annex 1 of FAO Treaty (ITPGRFA); b) GRs likely to be the causing pathogen of public health*
- e) Sets a **Register of Collections** in the Union*
- f) Establishes a mechanism for the recognition of **best practice***
- g) Establishes a mechanism for the **monitoring of user compliance** in the Union (**checkpoints**)*
- h) foresees a system of **checks***

## *Does not regulate access\_to GRs*

Access = exclusive competence of MSs

States exercise sovereign rights over GRs:

- ✓ Art. 15 CBD
- ✓ Art. 6 NP
- ✓ Art. 2 REG.



User compliance = concurrent competence EU and MSs

- ✓ Environment (art. 2, lett e – TFUE)
- ✓ Internal market = need for harmonization (art. 2, a) – TFUE)



# Due diligence obligation (art. 4 Reg. EU 511/2014)

User of GRs in EU  
Seeks, keeps and transfers to subsequent users

Internationally recognised  
certificate of compliance  
(IRCC)

If IRCC is not available

Inf. on:

- ✓ Date and place of access;
- ✓ Description of GR;
- ✓ source;
- ✓ Presence or absence of rights and obligations on ABS;
- ✓ Access permit;
- ✓ MAT

## Due diligence (art. 4 Reg. 511/2014)

If information is not sufficient or the legality of access is uncertain, the user has:

- Obtain the access permit and MAT


*or*

- Discontinue use



# Monitoring of user compliance (art. 7 Reg. 511/2014)

The user has to **DECLARE** the due diligence  
(and provide further info upon request of the NCA)



## **Research stage**

When the research project on GRs receives an external funding (public or private)

## **Final development of a product**


When a product has been developed via the utilization of GRs

# monitoraggio della conformità dell'utilizzatore (art.7 del regolamento UE 511/2014)

Utilizzatore UE deve dichiarare la dovuta diligenza  
(e fornire altre prove su richiesta del ANC)

nel momento in cui riceve un finanziamento  
alla ricerca che implica utilizzo di RG e/o TK

nella fase di sviluppo finale del prodotto  
realizzato mediante utilizzo di RG e/o TK



## *Research funding*

- ✓ Research projects involving utilization of GRs
- ✓ Public and private funding (both in the scope of Reg)
  
- ✓ When is the declaration due?
  - after the first instalment of funding is received
  - all genetic resources have been utilized
  - no later at time of final report or end of the project



## *Final development of a product*

- a) Market approval or authorization is requested for a product
- a) Notification required prior to placing for the first time a product on Union market
- a) Placing for the first time the product on EU market (no authorization or notification is required)
- a) The result of utilization is sold or transferred to natural or legal person in the EU (for a), b) and c) purposes)
- a) The result of utilization is sold or transferred to natural or legal person outside EU



## *Particular cases*

- Utilization of **PGRFA not in annex I** of the ITPGRFA (FAO Treaty) = no due diligence required if the provider country of PGRFA has decided to use the Standard Material Transfer Agreement (SMTA) for their exchange.
  
- Utilization of genetic resources determined to be (or likely to be) the **causing pathogen** of present or imminent public health emergency of international concern = extended deadline for due diligence obligation.

## *EU Register of Collections (art. 5 of EU Reg)*

- ✓ **Applies standard procedures for the exchange of GR samples in line with CBD;**
- ✓ **Transfers to third parties only documented GR samples**
- ✓ **Holds a register of the GR samples exchanged**
- ✓ **Uses unique indicators**
- ✓ **Uses traceability and monitoring tools for the exchange of GR samples.**







## Benefits:

- Users of GRs from the registered collection do not have to **seek** information on GRs
- The holder of the collection has to provide GRs together with related information (the duty is on him not on the user)
- Simplified access procedures

*Establishes a mechanism for the recognition of best practice*



**Association of users or interested parties**



**Submit an application to the EU Commission**





**Application verified by NCAs of all MSs (two months)**


**Positive evaluation= recognition of best practice**



## *System of checks (MSs)*

Checks are undertaken:

- a) By the NCA of the MS on users
- b) To assess the compliance to obligations under art. 4 and 7 of Reg;
- c) On the basis of a plan periodically reviewed/risk based approach
- d) On the basis of information from provider Countries or third parties



***MS acts with corrective and provisional immediate measures***

## Penalties

**Penalties must be:**

**a) Effective, dissuasive and proportionate**

**b) To be applied when art. 4 and 7 of Reg are breached**

**a) To be determined by MSs  
(upon MS competence)**



## FURTHER DOCUMENTATION EU

Commission Implementing Regulation (EU) 2015/1866 of 13 October 2015

art. 5 = EU register of collections



art. 7 = monitoring

art. 8 = best practice

Guidance document on the scope of application and core obligations of  
Regulation (EU) 511/2014

Sectoral horizontal Guidance





Bel : Belgium  
Cro : Croatia  
Lux : Luxemburg  
Net : Netherlands  
Por : Portugal  
Slo : Slovenia

*Implementation of the EU Regulation no. 511/2014  
state of play*

- ❑ The majority of the EU Member States have ratified the Protocol: no access regulations but only “Implementing Acts” transposing nationally the EU Regulation.
- ❑ The implementation of the EU Regulation is still at early stage
- ❑ Only 3DDD submitted (in DE) and no DDD submitted to the ABS CH
- ❑ 16 MSs have set administrative penalties (up to 2.000.000 euros) and 9 MSs also criminal penalties (imprisonment). But no penalties imposed yet.
- ❑ Only one collection successfully registered (in DE).
- ❑ Ongoing work on issues related to the EU Reg. scope (what in and what out)
- ❑ Lack of human and financial resources to set up a proper structure (few ABS staff or existing personnel employed on ABS in addition to their ordinary tasks )



***Thank you for the attention***



***Valentina.mauriello@gmail.com***